Skip to main content

Table 2 Proportion of responders to the tetanus (Boostrix) and pneumococcal (Pneumovax 23) vaccines 4 weeks after vaccination (week 6)

From: Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants

Responders Controla
(N = 41)
IXEb
(N = 38)
Difference in percentage response rates, IXE–control (95% CI)
Tetanus vaccine (> 4-fold increase)c 12 (29.3%) 16 (42.1%) 12.8 (− 8.0 to 32.4)
Pneumococcal vaccine (≥ 2-fold increase in > 70% serotypes)d 24 (58.5%) 26 (68.4%) 9.9 (− 11.1 to 29.5)
Pneumococcal vaccine (≥ 4-fold increase in > 50% serotypes)e 17 (41.5%) 17 (44.7%) 3.3 (− 17.8 to 24.0)
Pneumococcal vaccine (≥ 4-fold increase in > 70% serotypes)f 6 (14.6%) 4 (10.5%) − 4.1 (− 19.3 to 11.5)
  1. APAb anti-pneumococcal antibody, ATAb anti-tetanus antibody, CI confidence interval, IXE ixekizumab
  2. aControl arm = tetanus (Boostrix) and pneumococcal (Pneumovax 23) vaccines
  3. bIXE arm = IXE + tetanus (Boostrix) and pneumococcal (Pneumovax 23) vaccines
  4. cResponder to tetanus vaccine (Boostrix) defined as a post-vaccination ATAb level > 4-fold increase from baseline
  5. dResponder to pneumococcal vaccine (Pneumovax 23) defined as a ≥ 2-fold increase (100% increase) from baseline in APAb levels against > 70% of the 23 serotypes
  6. eResponder to pneumococcal vaccine (Pneumovax 23) defined as a ≥ 4-fold increase (300% increase) from baseline in APAb levels against > 50% of the 23 serotypes
  7. fResponder to pneumococcal vaccine (Pneumovax 23) defined as a ≥ 4-fold increase (300% increase) from baseline in APAb levels against > 70% of the 23 serotypes